FBT

First Trust NYSE Arca Biotechnology Index Fund

Up$140.32
+$1.76
(+1.27%)
As of 7:30:00 PM EDT | 11/20/19  |  Market Closed

FBT Trading Data

Open

$138.25

Low Price

$138.25

High Price

$140.62

Previous Last Price

$138.56

Bid Size

$138.88 X 700

Ask Size

$140.83 X 700

FBT Portfolio Data

AUM

$1,697,237,600

Shares

12,250

PE Ratio

21.14

Price / Book Ratio

4.35

Expense Ratio

0.57

Net Asset Value

$138.55

Volume

Volume

203,123

Avg. Volume (YDT)

167,284

Dollar Volume

$25,987,710

Weekly Avg. Volume

148,840

Monthly Avg. Volume

91,315

Quarterly Avg. Volume

256,402

FBT Fund Description

The First Trust NYSE Arca Biotechnology Index Fund is and exchange-traded index fund. The investment objective of the fund is to replicate as closely as possible, before fees and expenses, the price and yield of the NYSE Arca Biotechnology Index. The NYSE Arca Biotechnology Index is an equal dollar weighted index designed to measure the performance of a cross section of companies in the biotechnology industry that are primarily involved in the use of biological processes to develop products or provide services. Such processes include, but are not limited to, recombinant DNA technology, molecular biology, genetic engineering, monoclonal antibody-based technology, lipid/liposome technology, and genomics. The index is rebalanced quarterly based on closing prices on the third Friday in January, April, July and October to ensure that each component stock continues to represent approximately equal weight in the index.

FBT Chart

FBT Summary

Fund Family

First Trust Portfolios

Tracks This Index

First Trust NYSE Arca Biotechnology Index Fund

Inception Date

2006-06-19

Asset Class

Equity

Asset Class Size

Biotech

FBT Classification

Region (General)

Global

Region (Specific)

Sector

Health Care

Equity Index

Leveraged Family

FBT Holdings

Top 10 Holdings

First Trust Amex Biotech Index Fund ETF (FBT)
0%
QIAGEN N.V. (QGEN)
0%
Seattle Genetics Inc. (SGEN)
0%
Biogen Inc. (BIIB)
0%
Intercept Pharmaceuticals Inc. (ICPT)
0%
Neurocrine Biosciences Inc. (NBIX)
0%
Vertex Pharmaceuticals Incorporated (VRTX)
0%
Alkermes Plc (ALKS)
0%
ACADIA Pharmaceuticals Inc. (ACAD)
0%
Regeneron Pharmaceuticals Inc. (REGN)
0%

Total FBT Holdings

Total Holdings: 32

First Trust Amex Biotech Index Fund ETF (FBT)
0%
QIAGEN N.V. (QGEN)
0%
Seattle Genetics Inc. (SGEN)
0%
Biogen Inc. (BIIB)
0%
Intercept Pharmaceuticals Inc. (ICPT)
0%
Neurocrine Biosciences Inc. (NBIX)
0%
Vertex Pharmaceuticals Incorporated (VRTX)
0%
Alkermes Plc (ALKS)
0%
ACADIA Pharmaceuticals Inc. (ACAD)
0%
Regeneron Pharmaceuticals Inc. (REGN)
0%
Nektar Therapeutics (NKTR)
0%
Sarepta Therapeutics Inc. (SRPT)
0%
Incyte Corporation (INCY)
0%
United Therapeutics Corporation (UTHR)
0%
Alexion Pharmaceuticals Inc. (ALXN)
0%
Amgen Inc. (AMGN)
0%
Alnylam Pharmaceuticals Inc. (ALNY)
0%
BioMarin Pharmaceutical Inc. (BMRN)
0%
Agios Pharmaceuticals Inc. (AGIO)
0%
Bio-Techne Corporation (TECH)
0%
Ionis Pharmaceuticals Inc. (IONS)
0%
Grifols S.A. (ADR) (GRFS)
0%
Charles River Laboratories International Inc. (CRL)
0%
IQVIA Holdings Inc. (IQV)
0%
Exelixis Inc. (EXEL)
0%
Gilead Sciences Inc. (GILD)
0%
Illumina Inc. (ILMN)
0%
FibroGen Inc. (FGEN)
0%
Exact Sciences Corporation (EXAS)
0%
Ultragenyx Pharmaceutical Inc. (RARE)
0%
bluebird bio Inc. (BLUE)
0%
US Dollar ($USD)
0%

FBT Technicals

Alpha

-4.49

Beta

1.45

Leverage

Long

Standard Deviation

8.29

FBT Dividends

Dividend Date

2015-09-23

Latest Dividend

0.02

Annual Dividend

0

Annual Dividend Rate

0

Annual Dividend Yield

1.0E-5

FBT Performance

YTD Return

12.98%

1 Year Return

6.5%

3 Year Return

39.33%

5 Year Return

35.98%

10 Year Return

414.52%

FBT Related Articles

© 2019 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions.

Fundamental company data provided by Morningstar and Zacks Investment Research. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.